The investment will expand RNA T&T's operations and allow partners of both companies to leverage combined expertise in RNA-LNP therapeutics.

Advancing RNA therapeutics depends on understanding two critical questions: Where do drug candidates go, and what do they do ...

Acuitas Therapeutics, a leader in lipid nanoparticle (LNP) delivery systems for nucleic acid therapeutics, announced that it ...

Acuitas Therapeutics shelled out an undisclosed sum to acquire a majority stake in Montreal-based and privately held RNA Technologies & Therapeutics in a move to scale the latter’s operations around ...

PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) announced today that it has dosed the first subjects in a Phase 1/2a clinical trial (NCT06209177) of ARO-CFB, the ...

- Interim data from Phase 1/2a study demonstrate near complete inhibition in hemolytic activity and functional activity of alternative complement pathway “Dysregulated activation of the complement ...

A Regeneron Pharmaceuticals drug that lowers levels of a disease-driving protein has met the goals of a pivotal test in the rare disease generalized myasthenia gravis. Based on these results, ...